Clinical Trials
53 trialsNCT06690697 2024-11-15
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Phase 2 Recruiting
NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT00093457 2023-08-04
Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589420 2022-02-17
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT01444807 2021-09-17
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01731158 2019-02-06
BERAT
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01762150 2018-11-20
Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00112671 2018-07-27
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
National Cancer Institute (NCI)
Phase 2 Completed
NCT01502410 2018-06-26
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00090545 2018-06-14
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT00461851 2017-12-14
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Yale University
Phase 2 Completed
NCT00466752 2017-11-22
Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer
University of Washington
Phase 2 Completed
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01189370 2017-06-01
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
University of Kansas Medical Center
Phase 2 Completed
NCT02330783 2017-05-09
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT00126594 2016-09-16
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00467025 2016-03-23
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Amgen
Phase 2 Completed
NCT00445042 2016-03-17
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00618982 2015-12-24
Sorafenib Dose Escalation in Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00480389 2015-12-09
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
University Health Network, Toronto
Phase 2 Completed
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01342627 2015-10-06
SERCC
Centro di Riferimento Oncologico - Aviano
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00854620 2015-06-19
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Stanford University
Phase 2 Completed
NCT00694291 2015-03-06
Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT00661375 2014-12-25
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00079612 2014-12-19
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Bayer
Phase 2 Completed
NCT00678288 2014-12-11
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Bayer
Phase 2 Terminated
NCT00117637 2014-10-31
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00866320 2014-07-23
Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00586495 2013-12-13
Long-term Extension From RCC Phase II (11515)
Bayer
Phase 2 Completed
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT01222676 2013-08-12
Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00557830 2013-07-18
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00098618 2013-07-02
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn
NCT00101114 2013-02-28
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00301847 2013-02-11
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
National Cancer Institute (NCI)
Phase 2 Completed
NCT00452387 2011-09-16
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT01215266 2011-09-08
Sorafenib in Urothelium Cancer of Bladder
Association of Urologic Oncology (AUO)
Phase 2 Terminated
NCT00848640 2010-05-26
MERITS
Egyptian Foundation For Cancer Research
Phase 2 Completed
NCT01041482 2010-01-06
AGuo
ChineseAMS
Phase 2 Unknown
NCT00609401 2009-02-26
ROSORC
Italian Trial in Medical Oncology
Phase 2 Completed